Legend Biotech Corporation is a global biopharmaceutical company focused on the discovery development manufacturing and commercialization of novel cell therapies for oncology and other indications. The company leverages its proprietary technology and integrated capabilities to advance product candidates from research through clinical testing to market.

Legend Biotech Corporation generates revenue primarily from the sale of its approved CAR T therapy CARVYKTI which treats patients with relapsed or refractory multiple myeloma. The company also receives upfront payments milestone payments and royalties under its collaboration and licensing agreements with partners such as Janssen and Novartis.

Legend Biotech Corporation holds a notable position in the cell therapy arena especially as a developer of BCMA directed CAR T treatments for multiple myeloma. Its main competitors include other companies with approved BCMA targeting CAR T products such as Bristol Myers Squibb with Abecma and Janssen with Carvykti as well as emerging players like Arcellx and Caribou Biosciences. The company’s competitive advantages stem from its proprietary llama derived single domain antibody technology its dual binding CAR design and its integrated global development and manufacturing capabilities.

Legend Biotech Corporation serves patients with relapsed or refractory multiple myeloma through hospitals, cancer treatment centers and specialized healthcare providers in the United States, Europe and other regions where its CAR T therapy has received regulatory approval. Specific customer names are not disclosed in the filing.